Latest Conference Articles

November 21st 2020, 6:00pm

ESMO Asia Congress

November 21, 2020 - The addition of sugemalimab to chemotherapy demonstrated a statistically significant and clinically meaningful progression-free survival benefit in the frontline treatment of patients with metastatic non–small cell lung cancer versus placebo plus chemotherapy.

November 21st 2020, 5:13pm

ESMO Asia Congress

Timothy Price, MBBS, DHthSc, FRACP, discusses the safety and efficacy of AMG 510 in patients with advanced gastrointestinal cancers.

November 21st 2020, 5:01pm

ESMO Asia Congress

Maurice Perol, MD, discusses combination regimens comprised of chemotherapy and EGFR TKIs in the treatment of patients with EGFR-mutated advanced non–small cell lung cancer, as investigated in the OPAL trial presented during the ESMO Asia Virtual Congress 2020.

November 21st 2020, 4:19pm

ESMO Asia Congress

November 21, 2020 - Frontline sintilimab injection in combination with bevacizumab biosimilar injection resulted in a significant improvement in overall survival and progression-free survival per Independent Radiographic Review Committee versus sorafenib in patients with advanced unresectable hepatocellular carcinoma.

November 21st 2020, 3:23pm

ESMO Asia Congress

November 21, 2020 — Maintenance niraparib, when administered at an individualized starting dose, led to a 70% reduction in the risk of disease progression or death compared with placebo in Chinese patients with recurrent ovarian cancer who were in a complete or partial response to platinum-based chemotherapy.

November 20th 2020, 11:16pm

ESMO Asia Congress

The combination of atezolizumab and nab-paclitaxel led to a clinically meaningful overall survival benefit in treatment-naïve patients with locally advanced or metastatic triple-negative breast cancer who had PD-L1 expressing tumor-infiltrating immune cells.

November 20th 2020, 8:55pm

ESMO Asia Congress

November 20, 2020 - Patients from Asian countries with hormone receptor–positive, HER2-negative breast cancer may have a higher risk of disease recurrence than those from non-Asian countries, suggesting that this population may benefit from additional adjuvant treatment with abemaciclib.

November 20th 2020, 6:32pm

ESMO Asia Congress

November 20, 2020 - Osimertinib in combination with platinum plus pemetrexed was well tolerated in patients with previously untreated EGFR-mutated advanced non–small cell lung cancer.

November 20th 2020, 6:20pm

ESMO Asia Congress

The noninvasive blood-based targeted methylation assay ELSA-seq identified early cancers with high specificity and provided accurate predictions of the tissue of origin.

November 20th 2020, 5:25pm

ESMO Asia Congress

November 20, 2020 - Exploratory subgroup analysis of patients with extensive-stage small-cell lung cancer who derived a progression-free survival benefit with durvalumab plus platinum-based chemotherapy lasting longer than 12 months in the CASPIAN trial did not reveal any clinical characteristics that could serve as predictive factors for benefit with the monoclonal antibody.

November 17th 2020, 9:53pm

Ruesch Center Symposium

November 17, 2020 — The 11th Annual Ruesch Center Symposium, taking place virtually on November 20 to 21, 2020, will feature sessions that span innovations in gastrointestinal cancer, advances in nuclear imaging and therapy for neuroendocrine tumors, precision oncology web educational resource, and patient symposia, bringing participants together in a forum for discussion, networking, and debate on pressing issues in the field.

November 14th 2020, 3:57pm

November 14, 2020 - A novel combination comprised of the TKI cabozantinib plus the PD-1 inhibitor nivolumab and the CTLA-4 inhibitor ipilimumab is under exploration in treatment-naïve patients with intermediate or poor risk advanced or metastatic renal cell carcinoma in the phase 3 COSMIC-313 trial.

November 14th 2020, 3:16pm

Society for Immunotherapy of Cancer

Ira Winer, MD, PhD, discusses the tolerability of ALKS 4230 plus pembrolizumab in ovarian cancer.

November 14th 2020, 11:30am

November 14, 2020 – Treatment with the novel intratumoral immuotherapy agent PVSRIPO resulted in an overall response rate of 33% among all patients with anti–PD-1 refractory melanoma.

November 13th 2020, 11:39pm

November 13, 2020 - Treatment with the combination of eganelisib, a selective PI3K-γ inhibitor, and nivolumab demonstrated encouraging clinical activity and a favorable safety profile in patients with head and neck squamous cell carcinoma.

November 13th 2020, 11:39pm

Francesca Aroldi, discusses the early efficacy data with RP2 in advanced solid tumors.

November 13th 2020, 11:34pm

Daniel J. George, MD, discusses the expanding role of cabozantinib in renal cell carcinoma.

November 13th 2020, 10:44pm

November 13, 2020 – The addition of urelumab, an anti-CD137 agonist to the GVAX vaccine and nivolumab led to a 30% pathologic response rate and was associated with mild toxicity as neoadjuvant or adjuvant therapy in patients with resectable pancreatic ductal adenocarcinoma.

November 13th 2020, 9:46pm

November 13, 2020 - The combination of bempegaldesleukin and the PD-1 inhibitor nivolumab elicited a confirmed best overall response rate of 53% in efficacy-evaluable patients with metastatic melanoma.

November 13th 2020, 8:35pm

Society for Immunotherapy of Cancer

November 13, 2020 - The genetically modified herpes simplex-1 oncolytic RP2 demonstrated encouraging clinical activity and an acceptable safety profile in heavily pretreated patients with advanced solid tumors